Pharmacy Medical News about head and neck squamous cell carcinoma;erlotinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
European Journal of Cancer, 06/15/09

Thomas F et al. - Study concludes that erlotinib treatment may present criteria justifying dose individualisation but further studies, including more patients, are necessary to define the modalities of this adaptation.

Methods

Study was undertaken to:
- Analyse the impact of several covariates on the pharmacokinetics of erlotinib and its main metabolite (OSI-420) and
- Determine pharmacokinetic/pharmacodynamic (PK/PD) relationships
Plasma concns of erlotinib and OSI-420 of 42 pts were analysed to evaluate the impact of pts’ covariates on erlotinib PK
Presence of SNP in ABCB1 (2677G > T/A and 3435C > T), ABCG2 (421C > A) and CYP3A5 (6986G > A) was investigated
PK/PD relationships between plasma drug exposure (AUC) and early drug response or toxicity were also studied

Results

Covariates retained to predict erlotinib clearance were ALAT (alanine amino transferase), age and ABCG2 polymorphism
A significant link between drug exposure and the grade of skin rash was observed
However, early response to treatment was not correlated to the erlotinib AUC

<< Previous
Quality of pathologic response and surgery correlate with...

Next >>
A population-based clinical trial of irinotecan and carboplatin